Business context and reporting period
Important identification issue: The supplied filing is Panacea Acquisition Corp.’s Form 10-Q, not a Nuvation Bio Inc. filing. It reports from April 24, 2020 (inception) through June 30, 2020; the statements are unaudited. Panacea was a newly formed blank-check company seeking a business combination and had not commenced operations by quarter-end.
Financial position and results
| Metric | Reported amount or status |
|---|---|
| Revenue | None; no operating revenue was generated. |
| Formation and operating costs / net loss | $1,000 / $(1,000); basic and diluted loss per share was $(0.00). |
| Cash and total assets | $3,379 / $171,115, including $167,736 of deferred offering costs. |
| Current liabilities | $147,115, including $80,000 of related-party promissory notes and $66,115 of accrued offering costs. |
| Stockholders’ equity | $24,000. |
| Cash flow | Operating cash use was zero; financing activities provided $3,379 net. |
| Debt and liquidity | No long-term debt was reported. The $80,000 related-party note balance was repaid after quarter-end, upon the IPO closing on July 6. |
Margins are not meaningful because the company had no revenue. No prior comparable-period figures are presented; the reporting period covers only the company’s inception through quarter-end.
Material subsequent developments and outlook
- On July 6, 2020, Panacea completed an IPO of 14,375,000 units at $10 each, raising $143.75 million gross, and a private placement raising $4.875 million gross. It placed $143.75 million in the trust account and reported $3.39 million in transaction costs.
- A forward purchase agreement provides for a potential $25 million investment at the time of a business combination. Panacea also agreed to pay an affiliate $10,000 monthly for administrative services beginning July 1, and to pay underwriters a $5.031 million business-combination advisory fee if a transaction closes.
- The company must complete a business combination by July 6, 2022, subject to possible extension, or redeem public shares and liquidate. No target or transaction guidance was provided.
- Management said COVID-19 could adversely affect its search or a prospective target, but the specific impact was not determinable. The filing also identifies potential negative interest rates on trust assets as a risk to redemption value.
- Management reported effective disclosure controls at a reasonable-assurance level and no material change in internal control over financial reporting during the quarter. No legal proceedings were reported.
Most important facts to verify
- Confirm that this Panacea Acquisition Corp. filing is the intended document; it does not report Nuvation Bio’s results.
- Verify the post-quarter IPO, private placement, trust funding, transaction costs, and repayment of the related-party notes against subsequent filings.
- Review the business-combination deadline, redemption terms, dilution provisions, and warrant terms before assessing potential investor returns.
- Assess COVID-19 and negative-interest-rate risks, as well as the company’s dependence on completing a business combination.